Xerostomia is the medical term for the subjective complaint of dry mouth due to a lack of saliva. Xerostomia is sometimes colloquially called pasties, cottonmouth, drooth, doughmouth or des (like a desert). Several diseases, treatments and medications can cause xerostomia. It is also common in smokers. Treatment of xerostomia is a common clinical challenge in the oral medicine practice. Although some treatments have been used to improve the symptoms of xerostomia, none is completely satisfactory for the patients who suffer of this alteration. This review is aimed at presenting new developments for the treatment of xerostomia.
INTRODUCTION
Xerostomia is a symptom of oral dryness that occurs when salivary flow is not sufficient to compensate the fluid loss from the oral cavity. In the majority of cases, it results from loss of salivary gland hypofunction. [1] Xerostomia is a common problem. Its prevalence in the general population has been estimated to be 10-29%, women being more commonly affected than men. [2] Although more likely in middle to late life (perhaps reflecting the anticholinergic action of many drugs), xerostomia can affect young adults, but rarely children. [3, 4] The presence of saliva is usually taken for granted, and it is not required for any life-sustaining functions. Never the less, its diminution or absence can cause significant morbidity and a reduction in a patient's perceptions of quality of life. [5, 6] The primary constituents of saliva are water, proteins and electrolytes. [7] These components enhance taste, speech and swallowing, and facilitate irrigation, lubrication and protection of the mucous membranes in the upper digestive tract. [5] Additional physiological functions of saliva provide antimicrobial and buffering activities that protect the teeth from dental caries. [7] Upon meeting the dry mouth patients, dentists face a problem difficult to treat. Treatment with lubricants or salivary substitutes and salivary stimulation by gustatory or masticatory methods may generate an improvement, but xerostomia recurs once the treatment is interrupted. [8] Pharmacological agents, like pilocarpine HCl, have been studied extensively; nevertheless, more than one-third of the patients display adverse effects similar to those produced by other cholinergic drugs, including gastric upset, perspiration, Tachycardia, Bradycardia, Arrhythmia, increases of pulmonary secretions, muscular tone and urinary frequency and blurred vision. [9, 10] In a recent study, individuals with xerostomia expressed their wish of a functional non-pharmacological method for their treatment; however, none of the presently available treatments fulfills these expectations. [11] The objective of this review is to present the advances of neuroelectrostimulation for the treatment of xerostomia, based on the accumulated knowledge of neurological control of salivary secretion.
ETIOLOGY
Hyposalivation may occur with use of medications, as complications of connective tissue and autoimmune diseases, with radiation therapy to head and neck or with a number of other conditions. Hyposalivation contributes to a number of health problems. It can produce serious negative effects on the patients' quality of life by affecting dietary habits, nutritional status, speech, taste and tolerance to dental prosthesis and increasing the risk of oral infection, including candidiasis, susceptibility to dental caries, periodontal disease and tooth loss. [12] DRUGS ASSOCIATED WITH XEROSTOMIA* [5] 
Category
Generic name 
SALIVARY GLANDS
The parotid gland is, histologically, a serous type of gland and secretes 20% of the total saliva. The submandibular salivary gland is, histologically, a mixed type of gland and secretes 70% of the total saliva. The sublingual salivary gland is, histologically, a mixed type of gland and secretes 5% of the total saliva. In salivary glands, secretory granules containing salivary enzymes are discharged from the acinar cells to the ducts. About 1500 mL of saliva is secreted per day.
[13]
NEUROLOGICAL CONTROL OF SALIVARY SECRETION
Salivary gland secretion is regulated by the autonomic nervous system. Acetylcholine agonists act on the parasympathetic and muscarinic receptors of those exocrine glands, inducing high electrolyte containing salivary secretion, whereas sympathetic stimulation produces the protein component of the saliva. Thus, parasympathetic stimulation generates abundant saliva with low protein concentration and sympathetic stimulation produces little saliva with high protein concentration and viscosity. [14] Physiologically, salivary secretion is regulated by a three-component reflex arch, including (a) afferent receptors and nerves that carry impulses created by taste and mastication activities, 
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connection and processing nucleus (salivation center) and (c) an efferent reflex arm constituted by parasympathetic and sympathetic nerves bundles that separately, but in coordination, innervate the salivary gland blood vessels and acini. The afferent nerves carry impulses from the periphery to the salivation center in the medulla oblongata, which in turn directs signals to the efferent part of the reflex arch leading to salivation. [14, 15] The assessment of severity of xerostomia is done by subjective and objective techniques. The visual analogue scale, Zimmerman xerostomia questionnaire and late effect of normal tissues subjective objective management analysis (LENT SOMA) scale are some of the methods to find and grade the severity of xerostomia. The salivary gland secretory ratio (SGSR), determined by dynamic salivary 99mTcscintigraphy, is an objective measure of salivary gland function. [16, 17] Rydholm and associates conducted a study to explore the global effects of xerostomia, with a specific focus on the psychological and social consequences. Four main categories were identified in the study: [18] 1. Subjective discomfort: e.g. dryness or burning sensation. 2. Loss of function: e.g. articulation or swallowing. 3. Increased infection: e.g. oral thrush and ulcerations. 4. Psychological effects: Including shame, increased feelings of being a patient rather than a person and tendency to avoid social contact resulting in loneliness.
Xerostomia and associated symptoms have a considerable negative global impact, resulting in shame, anxiety, disappointments and verbal communication difficulties. They should therefore focus more on the management of xerostomia, which is often neglected in the palliative care. [19] Individuals with xerostomia often wish for a functional and non-pharmacological ("natural") cure. There thus remains a need for a treatment of xerostomia that is effective, convenient and safe. [11] More recently, the use of extraoral transcutaneous electric nerve stimulation (TENS) over the parotid gland was reported to increase saliva production in healthy individuals and patients with radiationinduced xerostomia, suggesting that TENS might directly stimulate the auriculotemporal nerve (efferent pathway) that supplies the secretomotor drive to the parotid gland. [20, 21] 
SALIVARY PACEMAKERS

First-generation electrostimulating devices
Neuroelectrostimulation to increase salivary secretion led to production of a device that was marketed in the USA (Salitron). The probe was applied to the intraoral mucosal surfaces by the user (between the dorsum of the tongue and the palate) for a few minutes each day and delivered a stimulating signal to sensitive neurons of the mouth to induce salivation [ Figure 1 ]. [22] [23] [24] Using this some what clumsy apparatus, it was found that such neuroelectrostimulation, when delivered repeatedly, led to an immediate (direct) response (increase of salivation as a result of the stimulation) and a cumulative long-term (indirect) response (sustained increase of basal salivary flow rate) as well as subjective improvement in symptomatic xerostomia. The device gave promising results in proof-of-principle clinical studies and did not give rise to any concomitant local or systemic adverse effects. However, its wider use was hampered by its large size, high price and lack of user-friendliness. To circumvent some of the limitations of this firstgeneration device, a European Commission-funded research consortium developed novel miniature intraoral neuro-electrostimulators to enhance salivary flow (Saliwell project). Two devices were produced, one designed to be part of a removable intraoral splint appliance (second-generation device) and the other to be fixed to an osteointegrated dental implant (thirdgeneration device). 
Second-generation devices
The second-generation salivary neuroelectrostimulator (GenNarino Saliwell Ltd. Germany) is a removable intraoral appliance produced for individual patients by using their teeth pattern molds. It is similar to a mouth guard used to treat temporomandibular joint disorders and bruxism. It has a horseshoe-like shape and fits on the lower dentition [ Figure 2 ]. It is designed so that it is easy to insert and remove by the patient himor herself. The electronic components are embedded within the appliance to allow safe and contaminationfree intraoral application. A remote control permits the patient to communicate with the device and modify its functions [ Figure 2 ].
The results of the study demonstrated that the device was relatively well tolerated by all patients and did not, with the exclusion criteria applied, give rise to any local or systemic adverse effect. Significant moistening of the oral mucosal membranes was recorded objectively (P < 0.0001), and diminished xerostomia was reported subjectively (P < 0.005). [25] The device was effective in reducing dryness of the mouth during application and up to 10 min after its removal. 
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Dental implant-based third-generation intraoral device
Some patients may require frequent and/or constant stimulation of the salivary glands. Therefore, a miniature neuroelectrostimulating device to be permanently implanted into the oral cavity was developed (the Saliwell Crown Saliwell Ltd. Germany) [ Figure 3 ]. Use of this dental implantbased neuroelectrostimulator avoids the inconvenience associated with the repeated application and removal of a splint-based stimulator. The components of the second-generation device were miniaturized and packaged into a device that has the dimensions and shape of a molar tooth. This device can be mounted on a commercially available osteointegrated implant. A wetness sensor has been embedded into the device to detect changes in wetness/dryness. This third-generation implantable device has been developed not only (1) to generate continuous or frequent stimuli, (2) to be applied into the oral cavity without interfering with regular oral functions and (3) to sense the wetness/dryness status of the oral cavity and automatically increase/decrease the stimulus within a preset range (autoregulatory mode) but also (4) to be controlled by the patient via a remote control.
The osteointegrated implant is positioned in the region of the lower third molar (wisdom tooth) to ensure close proximity to the lingual nerve that carries both afferent and efferent salivary impulses and to avoid interference with normal oral function. The necessary surgery is relatively straight forward, and the posterior location of the device ensures that there are no aesthetic concerns [ Figure 3] .
A clinical trial to investigate the long-term effect of this third-generation neuroelectrostimulatoron salivary function and symptoms of xerostomia is currently under way, and if the results are promising, it would be expected that this could become the most convenient and safe means to treat xerostomia. [11] CONCLUSION Xerostomia is the main clinical effect that interferes with nutrition and use of dentures, deteriorates oral hygiene and predisposes patients to oral candidiasis and dental problems (e.g. dental caries). Xerostomia and its associated symptoms have a considerable, negative global impact, resulting in shame, anxiety, disappointments and verbal communication difficulties.
Hyposalivation and xerostomia have multiple causes, but almost all of them, regardless of their etiology, affect in particular the resting (moisturizing) salivary flow. Neuroelectrostimulation of salivary glands takes the still remaining salivation reserves into therapeutic use. For patients with hyposalivation and xerostomiarelated impaired quality of life and those who require long-term therapy, the second-and third-generation intraoral neuroelectrostimulating devices may offer a new non-medicinal means of treatment. Preliminary results showing increased salivary secretion and progressive improvement of xerostomia symptoms are demonstrating the effectiveness of these intraoral devices. The prevention and treatment of xerostomia should be the primary concern and coordinated effort of a radiation oncologist and a dental surgeon now-a-days.
